

RECOVERY

Randomised Evaluation of COVID-19 Therapy

STOP-
COVID19 | Superiority Trial
Of Protease
inhibition in
COVID-19

Co-ordination of RECOVERY and STOP-COVID19 Trials

RECOVERY is a large-scale randomised trial open to every NHS Trust in the UK. Any COVID-19 patient in the UK over the age of 18 years may be invited to participate. RECOVERY is focussed on evaluating drugs that are available in sufficient volume to enrol a large number of patients and assess the impact of the drug on the risk of death.

STOP-COVID is a UK randomised trial being conducted in 15 UK centres to test Brensocatib compared with placebo improves clinical outcomes and reduces mortality in COVID-19 patients admitted to hospital.

RECOVERY and STOP-COVID have agreed that:

- Patients admitted to a hospital participating in both studies can be initially screened for participation in STOP-COVID19.
- If a patient is randomised to STOP-COVID19 they may then be co-enrolled into RECOVERY
- Due to interactions between BRENSOCATIB and Lopinavir-Ritonavir, patients participating in STOP-COVID19 should not receive Lopinavir-Ritonavir (i.e. it should be marked as “unsuitable” on the RECOVERY randomisation form). All other randomisation options in RECOVERY are available.
- RECOVERY and STOP-COVID19 will work closely together to share information on participating sites, interventions, and co-enrolments.